Antengene Corporation Limited (6996.HK) announced that on March 3, 2026, its wholly-owned subsidiaries Antengene Biologics Limited and Antengene (Hangzhou) Biologics Co., Ltd. entered into a license agreement with UCB. Under the agreement, Antengene will grant UCB an exclusive, worldwide license to develop, manufacture, and commercialize the investigational bispecific T-cell engager ATG-201 for B cell-related autoimmune diseases.

In return, Antengene will receive an upfront and near-term milestone payment of USD80.00 million, including an initial USD60.00 million payment and USD20.00 million contingent on certain conditions. Antengene will also be eligible for future success-based development and commercial milestone payments of up to USD1.10 billion, along with tiered royalties on potential net sales.

ATG-201 is designed as a CD19/CD3 bispecific T-cell engager, and Antengene plans to submit clinical trial applications in China and Australia in the first quarter of 2026. First-in-human Phase 1 studies will be conducted in these jurisdictions, with subsequent clinical development transferred to UCB.

UCB, listed on the Euronext Brussels (symbol: UCB), is a global biopharmaceutical company focused on severe diseases of the immune system or central nervous system, with revenue of EUR7.70 billion in 2025. Antengene will continue to leverage its technology platforms through this arrangement while advancing its pipeline, which spans from preclinical to commercial stages.